Intensity Tx - INTS Net Assets per Single Share

Graphic logo of Intensity Tx (INTS)

Intensity Therapeutics' development of anti-tumor technologies is independent of economic cycles and GDP. The bps metric trend demonstrates the estimated value of the firm's assets, where 3.16 shows the value of this parameter. The business is protected by US law and international regulations. The primary challenge remains modern chemotherapy methods, which compete with innovative immunomodulators in clinical practice.

INTS: Intensity Therapeutics Net Asset Value per Share 02/21/2024 - 10/27/2026

Intensity Therapeutics Inc - analytical breakdowns and key metrics (INTS)

- price and consensus price forecast:
Stock Quotes Intensity Tx|INTS - Analyst Forecast Prices
- market capitalization data:
Market Value Intensity Therapeutics, Inc.|INTS - Company Buyout Price
- book capitalization data:
Net Assets per Single Share Intensity Therapeutics|INTS - Total Stockholders' Equity|Market Value to Book Value Ratio intensitytherapeutics.com|INTS - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Intensity Therapeutics|INTS - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Intensity Tx|INTS - Company Cumulative Debt|Debt to Book Capitalization Ratio Intensity Therapeutics, Inc.
Fundamental company valuation:INTS - intensitytherapeutics.com
Flagship merchandise of Intensity Tx

Book value per share reflects the amount of equity minus all liabilities, allowing for an assessment of the company's actual asset value per share. The trend in the calculated book value per share helps investors determine asset undervaluation and the stability of Intensity Therapeutics (INTS), whose capitalization depends directly on the value of its intellectual property and the development of the breakthrough DARA technology for combating metastases.

Competitor analysis for Intensity Therapeutics

Accounting Value per Share ImmunityBio Corp IBRX|IMCR: Book Price of a Share|Janux Therapeutics - Net Assets per Single Share|RCUS (arcusbio.com) - Net Assets per Share|Net Assets per Single Share ZYME (Zymeworks)|Net Asset Value per Share TNGX|Net Assets per Single Share Iovance IOVA|Equity per Share Immatics Biotechnologies (IMTX)|Xencor, Inc. - Book Value per Share|compasstherapeutics.com - Accounting Value per Share|REPL (Replimune) - Net Assets per Single Share|LYEL: Net Asset Value per Share|Innate Pharma, S.A. (IPHA) - Net Assets per Single Share|PYXS (Pyxis Oncology) - Net Assets per Single Share|Net Assets per Single Share CGEN (Compugen Ltd)|Net Asset Value per Share iobiotech.com|STRO: Book Value per Share|Book Value of One Share MiNK Therapeutics Inc. INKT|HOWL: Accounting Value per Share|IMMX - Net Asset Value per Share|Accounting Value per Share ALX Oncology Holdings (ALXO)|CUE - Accounting Value of a Share|pdsbiotech.com - Book Value per Share|SONN (Sonnet BioTherapeutics Holdings) - Net Assets per Share|Net Assets per Single Share MAIA|Accounting Value per Share LIMN|Net Assets per Single Share LVTX (LAVA Therapeutics N.V.)|Accounting Value per Share nextcure.com NXTC|Accounting Value per Share LPTX (Leap Therapeutics)|Sensei Biotherapeutics Inc - Book Value per Share|Synthetic Biologics (TOVX) - Net Assets per Single Share|GRTS: Equity per Share|Net Assets per Single Share KA|Net Asset Value per Share neximmune.com|Turnstone Biologics Corp - Accounting Value per Share|Book Value of One Share Vaccinex Inc. (VCNX)|Accounting Value per Share Harpoon Tx